CD117 (c-Kit) Monoclonal Antibody (YB5.B8), eBioscience™, Invitrogen™

Description

• Description: The YB5.B8 monoclonal antibody reacts with human CD117, also known as c-Kit , Steel factor receptor and stem cell factor receptor
• A member of the tyrosine kinase receptor family, this 145 kDa molecule is expressed by hematopoietic progenitor cell subsets and mast cells
• The interaction of c-Kit and Steel factor promotes proliferation and differentiation of hematopoietic progenitor cells and mast cell differentiation
• CD117 is also expressed by melanocytes and plays a role in signaling and activation of these cells
• Applications Reported: YB5.B8 has been reported for use in flow cytometric analysis, immunoprecipitation, and immunohistochemical staining of frozen tissue sections
• Applications Tested: The YB5.B8 antibody has been tested by flow cytometric analysis of the TF-1 cell line, a human erythroleukemia cell line
• This can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• KIT (c-KIT) is a proto-oncogene and a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor)
• KIT was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit
• KIT together with its ligand regulates growth and activation of a variety of hemopoietic and non-hemopoietic cells
• Mutations in KIT are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism
• Recently, deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed at curbing neoplastic mast cell growth
• c-Kit is expressed in hematopoietic stem cells, germ cells, mast cells and gastrointestinal tract cajal cells
• Upon binding of its ligand stem cell factor (SCF), c-kit dimerizes, resulting in receptor activation and autophosphorylation of various tyrosine residues including tyrosine 703 located on the cytoplasmic domain of the receptor
• This modification allows docking of Grb2 and activation of the Ras/ERK signaling pathway
• SCF/c-kit can activate multiple downstream signaling pathways including PI3K, PLC-gamma and JAK/STAT
• c-kit receptor activation is essential for hematopoiesis, stem cell maintenance and gametogenesis.